Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis
- 15 December 2007
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 35 (5) , 933-941
Abstract
Despite accumulating reports on the clinical value of 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET) and magnetic resonance imaging (MRI) in the assessment of cardiac sarcoidosis, no studies have systematically compared the images of these modalities.Keywords
This publication has 41 references indexed in Scilit:
- Multimodality Imaging of Cardiac Sarcoidosis Before and After Steroid TherapyCirculation, 2006
- Cardiac sarcoidosis in a 60 year old womanHeart, 2006
- Evaluation of the Accuracy of Gadolinium-Enhanced Cardiovascular Magnetic Resonance in the Diagnosis of Cardiac SarcoidosisJACC, 2005
- Cardiac Sarcoidosis: Spectrum of MRI FeaturesAmerican Journal of Roentgenology, 2005
- The use of 2-[18F]fluoro-2-deoxy-d-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomographyInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- Two-dimensional echocardiographic findings in systemic sarcoidosisThe American Journal of Cardiology, 1989
- Influence of the renin—angiotensin system on the autoregulation of renal blood flow and glomerular filtration rate in conscious dogsActa Physiologica Scandinavica, 1988
- ECG Abnormalities in Patients with SarcoidosisActa Medica Scandinavica, 1983
- Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.Circulation, 1978
- Cardiac sarcoidosisThe American Journal of Cardiology, 1978